Oncologists at Memorial Sloan-Kettering may have just made a breakthrough in treating one of the world’s deadliest cancers. In a trial of a new mRNA vaccine administered alongside immunotherapy and chemotherapy, eight out of 16 early-stage pancreatic cancer patients showed strong positive responses, and only two of those eight saw their cancer return within ~3 years after treatment.
Pancreatic cancer typically comes back within a year, on average, for patients who only get chemotherapy and surgery. A German biotechnology company produced each patient’s individualized mRNA vaccine based on samples of their tumors in just nine weeks.
No comments:
Post a Comment